1. Home
  2. REGN vs LOW Comparison

REGN vs LOW Comparison

Compare REGN & LOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REGN
  • LOW
  • Stock Information
  • Founded
  • REGN 1988
  • LOW 1946
  • Country
  • REGN United States
  • LOW United States
  • Employees
  • REGN N/A
  • LOW N/A
  • Industry
  • REGN Biotechnology: Pharmaceutical Preparations
  • LOW RETAIL: Building Materials
  • Sector
  • REGN Health Care
  • LOW Consumer Discretionary
  • Exchange
  • REGN Nasdaq
  • LOW Nasdaq
  • Market Cap
  • REGN 63.4B
  • LOW 123.4B
  • IPO Year
  • REGN 1991
  • LOW N/A
  • Fundamental
  • Price
  • REGN $547.67
  • LOW $224.51
  • Analyst Decision
  • REGN Buy
  • LOW Buy
  • Analyst Count
  • REGN 23
  • LOW 24
  • Target Price
  • REGN $907.39
  • LOW $279.00
  • AVG Volume (30 Days)
  • REGN 1.2M
  • LOW 2.3M
  • Earning Date
  • REGN 04-29-2025
  • LOW 05-20-2025
  • Dividend Yield
  • REGN 0.32%
  • LOW 2.05%
  • EPS Growth
  • REGN 16.49
  • LOW N/A
  • EPS
  • REGN 39.43
  • LOW 12.23
  • Revenue
  • REGN $14,085,700,000.00
  • LOW $83,674,000,000.00
  • Revenue This Year
  • REGN $2.38
  • LOW $1.91
  • Revenue Next Year
  • REGN $7.65
  • LOW $3.62
  • P/E Ratio
  • REGN $14.23
  • LOW $18.35
  • Revenue Growth
  • REGN 7.52
  • LOW N/A
  • 52 Week Low
  • REGN $520.50
  • LOW $206.39
  • 52 Week High
  • REGN $1,211.20
  • LOW $287.01
  • Technical
  • Relative Strength Index (RSI)
  • REGN 38.69
  • LOW 50.73
  • Support Level
  • REGN $542.44
  • LOW $221.70
  • Resistance Level
  • REGN $615.61
  • LOW $227.73
  • Average True Range (ATR)
  • REGN 22.06
  • LOW 4.89
  • MACD
  • REGN -0.13
  • LOW 1.04
  • Stochastic Oscillator
  • REGN 28.57
  • LOW 81.41

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About LOW Lowe's Companies Inc.

Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its commercial and professional business clients to 30% from less than 20% in the past six years. We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.

Share on Social Networks: